These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

984 related articles for article (PubMed ID: 20223286)

  • 1. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry powder inhaler formulation.
    Telko MJ; Hickey AJ
    Respir Care; 2005 Sep; 50(9):1209-27. PubMed ID: 16122404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids.
    Hadinoto K; Phanapavudhikul P; Kewu Z; Tan RB
    Int J Pharm; 2007 Mar; 333(1-2):187-98. PubMed ID: 17084567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
    Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
    Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effervescent dry powder for respiratory drug delivery.
    Ely L; Roa W; Finlay WH; Löbenberg R
    Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formation, characterization, and fate of inhaled drug nanoparticles.
    Zhang J; Wu L; Chan HK; Watanabe W
    Adv Drug Deliv Rev; 2011 May; 63(6):441-55. PubMed ID: 21118707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
    Cheow WS; Ng ML; Kho K; Hadinoto K
    Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particle engineering techniques for inhaled biopharmaceuticals.
    Shoyele SA; Cawthorne S
    Adv Drug Deliv Rev; 2006 Oct; 58(9-10):1009-29. PubMed ID: 17005293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry powder inhalers for pulmonary drug delivery.
    Frijlink HW; De Boer AH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):67-86. PubMed ID: 16296721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and testing of particulate formulations for the nasal delivery of antibodies.
    Kaye RS; Purewal TS; Alpar OH
    J Control Release; 2009 Apr; 135(2):127-35. PubMed ID: 19059291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K; Katona G; Csóka I; Ambrus R
    J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on the Pulmonary Delivery System of Apigenin-Loaded Albumin Nanocarriers with Antioxidant Activity.
    Pápay ZE; Kósa A; Böddi B; Merchant Z; Saleem IY; Zariwala MG; Klebovich I; Somavarapu S; Antal I
    J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):274-288. PubMed ID: 28282259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.